Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2281 to 2295 of 9015 results

  1. Doravirine-islatravir for previously untreated HIV-1 infection [TSID12172]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  2. Doravirine–islatravir for treating HIV-1 in people with virological suppression on bictegravir, emtricitabine and tenofovir alafenamide combination treatment [TSID12171]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  3. Percutaneous thrombectomy for intermediate-risk and high-risk acute pulmonary embolism

    In development Reference number: GID-HTG10169 Expected publication date:  07 April 2027

    HealthTech guidance
    In development

  4. MMprofiler for estimating risk in newly diagnosed multiple myeloma

    In development Reference number: GID-HTG10153 Expected publication date:  06 May 2027

    HealthTech guidance
    In development

  5. Larotrectinib for treating NTRK fusion-positive advanced solid tumours (MA review of TA630) [ID6292]

    In development Reference number: GID-TA11565 Expected publication date:  18 November 2026

    Technology appraisal guidance
    In development

  6. Belzutifan for treating advanced pheochromocytoma or paraganglioma [ID6719]

    Awaiting development Reference number: GID-TA11928 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  7. Artificial intelligence (AI) technologies to help detect fractures on X-rays in urgent care

    Awaiting development Reference number: GID-HTG10531 Expected publication date: TBC

    HealthTech guidance
    Awaiting development

  8. Durvalumab (Imfinzi) +/- bevacizumab (Avastin) for hepatocellular carcinoma [TSID10736]

    Awaiting development Reference number: GID-TA11076 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  9. Polycystic ovary syndrome: assessment and management

    In development Reference number: GID-NG10436 Expected publication date:  09 December 2026

    NICE guideline
    In development

  10. Avapritinib for treating inadequately controlled moderate to severe indolent systemic mastocytosis [ID6578]

    In development Reference number: GID-TA11772 Expected publication date:  03 September 2026

    Technology appraisal guidance
    In development

  11. Seladelpar for previously treated primary biliary cholangitis [ID6429]

    In development Reference number: GID-TA11540 Expected publication date:  09 July 2026

    Technology appraisal guidance
    In development

  12. Ianalumab for treating active Sjogren's syndrome ID6634: consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

    We are listening to your views on this Technology appraisal guidance. Comments close 4 June 2026.

    Technology appraisal guidance
    In consultation

  13. Ianalumab for treating active Sjogren's syndrome ID6634

    In development Reference number: GID-TA11836 Expected publication date: TBC

    Technology appraisal guidance
    In development

  14. Leriglitazone for treating cerebral adrenoleukodystrophy in boys and men 2 years and over [ID3903]

    In development Reference number: GID-TA11445 Expected publication date: TBC

    Technology appraisal guidance
    In development

  15. Dostarlimab for previously treated advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency (MA review of TA779) [ID6326]

    In development Reference number: GID-TA11764 Expected publication date:  23 July 2026

    Technology appraisal guidance
    In development